Ataxia-telangiectasia clinical trial landscape and the obstacles to overcome

References

• Rothblum-Oviatt C, Wright J, Lefton-Greif MA, et al. Ataxia telangiectasia: a review. Orphanet J Rare Dis. 2016 Nov 25;11(1):159. doi: 10.1186/s13023-016-0543-7
   PubMedGoogle Scholar
• Crawford TO, Skolasky RL, Fernandez R, et al. Survival probability in ataxia telangiectasia. Arch Dis Child. 2006 [2006 Jul];91(7):610–611. doi: 10.1136/adc.2006.094268
   PubMed Web of Science ®Google Scholar
• Laitman Y, Nielsen SM, Bernstein-Molho R, et al. Cancer risks associated with heterozygous ATM loss of function and missense pathogenic variants based on multigene panel analysis. Breast Cancer Res Treat. 2022 Nov;196(2):355–361. doi: 10.1007/s10549-022-06723-z
   PubMed Web of Science ®Google Scholar
• Kotchetkoff ECA, Souza FIS, Fonseca FLA, et al. Assessing cardiovascular risk in ATM heterozygotes. Rev Assoc Med Bras (1992). 2018 Feb;64(2):148–153. doi: 10.1590/1806-9282.64.02.148
   PubMed Web of Science ®Google Scholar
• Caputi C, Federici G, Soddu S, et al. Mild neurological phenotype associated with hypomorphic variants in the ataxia-telangiectasia mutated gene. Mov Disord Clin Pract. 2023 Jan;10(1):124–129. doi: 10.1002/mdc3.13618
   PubMed Web of Science ®Google Scholar
• Mandola AB, Reid B, Sirror R, et al. Ataxia telangiectasia diagnosed on newborn screening-case cohort of 5 years’ experience. Front Immunol. 2019;10:2940. doi: 10.3389/fimmu.2019.02940
   PubMed Web of Science ®Google Scholar
• Donath H, Woelke S, Schubert R, et al. Neurofilament light chain is a biomarker of neurodegeneration in ataxia telangiectasia. Cerebellum. 2022 Feb;21(1):39–47. doi: 10.1007/s12311-021-01257-4
   PubMed Web of Science ®Google Scholar
• Veenhuis SJG, Gupta AS, de Gusmão CM, et al. Neurofilament light chain: a novel blood biomarker in patients with ataxia telangiectasia. Eur J Paediatr Neurol. 2021 May;32:93–97.
   PubMed Web of Science ®Google Scholar
• Zielen S, Duecker RP, Woelke S, et al. Simple measurement of IgA predicts immunity and mortality in ataxia-telangiectasia. J Clin Immunol. 2021 Nov;41(8):1878–1892. doi: 10.1007/s10875-021-01090-8
   PubMed Web of Science ®Google Scholar
• McGrath-Morrow SA, Collaco JM, Detrick B, et al. Serum interleukin-6 levels and pulmonary function in ataxia-telangiectasia. J Pediatr. 2016 [2016 Feb2];171:256–261.e1.
   PubMed Web of Science ®Google Scholar
• Solomon GM, Marshall SG, Ramsey BW, et al. Breakthrough therapies: cystic fibrosis (CF) potentiators and correctors. Pediatr Pulmonol. 2015 Oct;50(Suppl 400 40):S3–s13. doi: 10.1002/ppul.23240
   PubMedGoogle Scholar
• Havens MA, Hastings ML. Splice-switching antisense oligonucleotides as therapeutic drugs. Nucleic Acids Res. 2016 Aug 19;44(14):6549–6563.
   PubMed Web of Science ®Google Scholar
• Du L, Pollard JM, Gatti RA. Correction of prototypic ATM splicing mutations and aberrant ATM function with antisense morpholino oligonucleotides. Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):6007–6012.
   PubMed Web of Science ®Google Scholar
• Nakamura K, Du L, Tunuguntla R, et al. Functional characterization and targeted correction of ATM mutations identified in Japanese patients with ataxia-telangiectasia. Human Mutation. 2012 Jan;33(1):198–208. doi: 10.1002/humu.21632
   PubMed Web of Science ®Google Scholar
• Cavalieri S, Pozzi E, Gatti RA, et al. Deep-intronic ATM mutation detected by genomic resequencing and corrected in vitro by antisense morpholino oligonucleotide (AMO). Eur J Hum Genet. 2013 Jul;21(7):774–778. doi: 10.1038/ejhg.2012.266
   PubMed Web of Science ®Google Scholar
• Du L, Kayali R, Bertoni C, et al. Arginine-rich cell-penetrating peptide dramatically enhances AMO-mediated ATM aberrant splicing correction and enables delivery to brain and cerebellum. Hum Mol Genet. 2011 Aug 15;20(16):3151–3160.
   PubMed Web of Science ®Google Scholar
• Chiriboga CA. Nusinersen for the treatment of spinal muscular atrophy. Expert Rev Neurotherapeutics. 2017 Oct;17(10):955–962. doi: 10.1080/14737175.2017.1364159
   PubMed Web of Science ®Google Scholar
• Cornelissen L, Donado C, Yu TW, et al. Modified sensory testing in non-verbal patients receiving novel intrathecal therapies for neurological disorders. Front Neurol. 2022;13:664710. doi: 10.3389/fneur.2022.664710
   PubMed Web of Science ®Google Scholar
• Hudry E, Vandenberghe LH. Therapeutic AAV gene transfer to the nervous system: a clinical reality. Neuron. 2019 Mar 6;101(5):839–862.
   PubMed Web of Science ®Google Scholar
• Flotte TR, Cataltepe O, Puri A, et al. AAV gene therapy for Tay-Sachs disease. Nature Med. 2022 Feb;28(2):251–259. doi: 10.1038/s41591-021-01664-4
   PubMed Web of Science ®Google Scholar
• Bourseguin J, Cheng W, Talbot E, et al. Persistent DNA damage associated with ATM kinase deficiency promotes microglial dysfunction. Nucleic Acids Res. 2022 Mar 21;50(5):2700–2718.
   PubMed Web of Science ®Google Scholar
• Aguado J, Chaggar HK, Gómez-Inclán C, et al. Inhibition of the cGAS-STING pathway ameliorates the premature senescence hallmarks of ataxia-telangiectasia brain organoids. Aging Cell. 2021 Sep;20(9):e13468. doi: 10.1111/acel.13468
   PubMed Web of Science ®Google Scholar
• Stern N, Hochman A, Zemach N, et al. Accumulation of DNA damage and reduced levels of nicotine adenine dinucleotide in the brains of atm-deficient mice. J Biol Chem. 2002 Jan 4;277(1):602–608.
   PubMed Web of Science ®Google Scholar
• Kirshner M, Galron R, Frenkel D, et al. Malfunctioning DNA damage response (DDR) leads to the degeneration of nigro-striatal pathway in mouse brain. J Mol Neurosci. 2012 Mar;46(3):554–568. doi: 10.1007/s12031-011-9643-y
   PubMed Web of Science ®Google Scholar
• Guo Z, Kozlov S, Lavin MF, et al. ATM activation by oxidative stress. Science. 2010 [2010 Oct22];330(6003):517–521. doi: 10.1126/science.1192912
   PubMed Web of Science ®Google Scholar
• Ambrose M, Gatti RA. Pathogenesis of ataxia-telangiectasia: the next generation of ATM functions. Blood. 2013 May 16;121(20):4036–4045.
   PubMed Web of Science ®Google Scholar
• Chaudhary MW, Al-Baradie RS. Ataxia-telangiectasia: future prospects. Appl Clin Genet. 2014;7:159–167. doi: 10.2147/TACG.S35759
   PubMedGoogle Scholar
• Maciejczyk M, Mikoluc B, Pietrucha B, et al. Oxidative stress, mitochondrial abnormalities and antioxidant defense in ataxia-telangiectasia, bloom syndrome and Nijmegen breakage syndrome. Redox Biol. 2017 Apr;11:375–383.
   PubMed Web of Science ®Google Scholar
• Rotman G, Shiloh Y. The ATM gene and protein: possible roles in genome surveillance, checkpoint controls and cellular defence against oxidative stress. Cancer Surv. 1997;29:285–304.
   PubMedGoogle Scholar
• Green MH, Marcovitch AJ, Harcourt SA, et al. Hypersensitivity of ataxia-telangiectasia fibroblasts to a nitric oxide donor. Free Radic Biol Med. 1997;22(1–2):343–347. doi: 10.1016/S0891-5849(96)00336-X
   PubMed Web of Science ®Google Scholar
• Mitiagin Y, Barzilai A. Ataxia-telangiectasia mutated plays an important role in cerebellar integrity and functionality. Neural Regen Res. 2023 Mar;18(3):497–502. doi: 10.4103/1673-5374.350194
   PubMed Web of Science ®Google Scholar
• Barlow C, Dennery PA, Shigenaga MK, et al. Loss of the ataxia–telangiectasia gene product causes oxidative damage in target organs. Proc Natl Acad Sci USA. 1999 Aug 17;96(17):9915–9919.
   PubMed Web of Science ®Google Scholar
• Quick KL, Dugan LL. Superoxide stress identifies neurons at risk in a model of ataxia-telangiectasia. Ann Neurol. 2001 May;49(5):627–635. doi: 10.1002/ana.1005
   PubMed Web of Science ®Google Scholar
• Kamsler A, Daily D, Hochman A, et al. Increased oxidative stress in ataxia telangiectasia evidenced by alterations in redox state of brains from atm-deficient mice. Cancer Res. 2001 Mar 1;61(5):1849–1854.
   PubMed Web of Science ®Google Scholar
• Yang B, Dan X, Hou Y, et al. NAD(+) supplementation prevents STING-induced senescence in ataxia telangiectasia by improving mitophagy. Aging Cell. 2021 Apr;20(4):e13329. doi: 10.1111/acel.13329
   PubMed Web of Science ®Google Scholar
• Chen P, Peng C, Luff J, et al. Oxidative stress is responsible for deficient survival and dendritogenesis in purkinje neurons from ataxia-telangiectasia mutated mutant mice. J Neurosci. 2003 Dec 10;23(36):11453–11460.
   PubMed Web of Science ®Google Scholar
• Browne SE, Roberts LJ 2nd, Dennery PA, et al. Treatment with a catalytic antioxidant corrects the neurobehavioral defect in ataxia-telangiectasia mice. Free Radic Biol Med. 2004 Apr 1;36(7):938–942.
   PubMed Web of Science ®Google Scholar
• Reliene R, Fischer E, Schiestl RH. Effect of N-acetyl cysteine on oxidative DNA damage and the frequency of DNA deletions in atm-deficient mice. Cancer Res. 2004 Aug 1;64(15):5148–5153.
   PubMed Web of Science ®Google Scholar
• Reliene R, Schiestl RH. Antioxidant N-acetyl cysteine reduces incidence and multiplicity of lymphoma in atm deficient mice. DNA Repair (Amst). 2006 Jul 13;5(7):852–859.
   PubMed Web of Science ®Google Scholar
• Fang EF, Kassahun H, Croteau DL, et al. NAD(+) replenishment improves lifespan and healthspan in ataxia telangiectasia models via mitophagy and DNA repair. Cell Metab. 2016 Oct 11;24(4):566–581.
   PubMed Web of Science ®Google Scholar
• Veenhuis SJG, van Os NJH, Janssen A, et al. Nicotinamide riboside improves ataxia scores and immunoglobulin levels in ataxia telangiectasia. Mov Disord. 2021 Dec;36(12):2951–2957. doi: 10.1002/mds.28788
   PubMedGoogle Scholar
• Steinbrücker K, Tiefenthaler E, Schernthaner EM, et al. Nicotinamide riboside for ataxia telangiectasia: a report of an early treated individual. Neuropediatrics. 2023 Feb;54(1):78–81. doi: 10.1055/a-1959-9404
   PubMedGoogle Scholar
• Valentin-Vega YA, Maclean KH, Tait-Mulder J, et al. Mitochondrial dysfunction in ataxia-telangiectasia. Blood. 2012 Feb 9;119(6):1490–1500.
   PubMed Web of Science ®Google Scholar
• Blignaut M, Harries S, Lochner A, et al. Ataxia telangiectasia mutated protein kinase: a potential master puppeteer of oxidative stress-induced metabolic recycling. Oxid Med Cell Longev. 2021;2021:8850708. doi: 10.1155/2021/8850708
   PubMed Web of Science ®Google Scholar
• Yeo AJ, Subramanian GN, Chong KL, et al. An anaplerotic approach to correct the mitochondrial dysfunction in ataxia-telangiectasia (A-T). Mol Metab. 2021 Dec;54:101354.
   PubMed Web of Science ®Google Scholar
• Yang Y, Hui CW, Li J, et al. The interaction of the atm genotype with inflammation and oxidative stress. PLoS One. 2014;9(1):e85863. doi: 10.1371/journal.pone.0085863
   PubMed Web of Science ®Google Scholar
• Quek H, Luff J, Cheung K, et al. Rats with a missense mutation in atm display neuroinflammation and neurodegeneration subsequent to accumulation of cytosolic DNA following unrepaired DNA damage. J Leukocyte Biol. 2017 Apr;101(4):927–947. doi: 10.1189/jlb.4VMA0716-316R
   PubMed Web of Science ®Google Scholar
• Buoni S, Zannolli R, Sorrentino L, et al. Betamethasone and improvement of neurological symptoms in ataxia-telangiectasia. Arch Neurol. 2006 Oct;63(10):1479–1482. doi: 10.1001/archneur.63.10.1479
   PubMedGoogle Scholar
• Broccoletti T, Del Giudice E, Amorosi S, et al. Steroid-induced improvement of neurological signs in ataxia-telangiectasia patients. Eur J Neurol. 2008 Mar;15(3):223–228. doi: 10.1111/j.1468-1331.2008.02060.x
   PubMed Web of Science ®Google Scholar
• Russo I, Cosentino C, Del Giudice E, et al. In ataxia-teleangiectasia betamethasone response is inversely correlated to cerebellar atrophy and directly to antioxidative capacity. Eur J Neurol. 2009 Jun;16(6):755–759. doi: 10.1111/j.1468-1331.2009.02600.x
   PubMed Web of Science ®Google Scholar
• Zannolli R, Buoni S, Betti G, et al. A randomized trial of oral betamethasone to reduce ataxia symptoms in ataxia telangiectasia. Mov Disord. 2012 Sep 1;27(10):1312–1316.
   PubMed Web of Science ®Google Scholar
• Broccoletti T, Del Giudice E, Cirillo E, et al. Efficacy of very-low-dose betamethasone on neurological symptoms in ataxia-telangiectasia. Eur J Neurol. 2011 Apr;18(4):564–570. doi: 10.1111/j.1468-1331.2010.03203.x
   PubMed Web of Science ®Google Scholar
• Quarantelli M, Giardino G, Prinster A, et al. Steroid treatment in ataxia-telangiectasia induces alterations of functional magnetic resonance imaging during prono-supination task. Eur J Paediatr Neurol. 2013 Mar;17(2):135–140. doi: 10.1016/j.ejpn.2012.06.002
   PubMed Web of Science ®Google Scholar
• Cirillo E, Del Giudice E, Micheli R, et al. Minimum effective betamethasone dosage on the neurological phenotype in patients with ataxia-telangiectasia: a multicenter observer-blind study. Eur J Neurol. 2018 Jun;25(6):833–840. doi: 10.1111/ene.13606
   PubMed Web of Science ®Google Scholar
• Hasegawa S, Kumada S, Tanuma N, et al. Long-term evaluation of low-dose betamethasone for ataxia telangiectasia. Pediatr Neurol. 2019 Nov;100:60–66.
   PubMed Web of Science ®Google Scholar
• Saberi-Karimian M, Beyraghi-Tousi M, Jamialahmadi T, et al. The positive short-term effect of dexamethasone on ataxia symptoms in a patient with ataxia-telangiectasia: a case report. Clin Case Rep. 2022 May;10(5):e05895. doi: 10.1002/ccr3.5895
   PubMed Web of Science ®Google Scholar
• Mambrini G, Mandolini M, Rossi L, et al. Ex vivo encapsulation of dexamethasone sodium phosphate into human autologous erythrocytes using fully automated biomedical equipment. Int J Pharm. 2017 Jan 30;517(1–2):175–184.
   PubMedGoogle Scholar
• Coker SA, Szczepiorkowski ZM, Siegel AH, et al. A study of the pharmacokinetic properties and the in vivo kinetics of erythrocytes loaded with dexamethasone sodium phosphate in healthy volunteers. Transfus Med Rev. 2018 Apr;32(2):102–110. doi: 10.1016/j.tmrv.2017.09.001
   PubMed Web of Science ®Google Scholar
• Chessa L, Leuzzi V, Plebani A, et al. Intra-erythrocyte infusion of dexamethasone reduces neurological symptoms in ataxia teleangiectasia patients: results of a phase 2 trial. Orphanet J Rare Dis. 2014 Jan 9;9(1):5.
   PubMedGoogle Scholar
• Leuzzi V, Micheli R, D’Agnano D, et al. Positive effect of erythrocyte-delivered dexamethasone in ataxia-telangiectasia. Neurol(r) Neuroimmunol Neuroinflammation. 2015 Jun;2(3):e98. doi: 10.1212/NXI.0000000000000098
   PubMedGoogle Scholar
• Menotta M, Biagiotti S, Spapperi C, et al. ATM splicing variants as biomarkers for low dose dexamethasone treatment of A-T. Orphanet J Rare Dis. 2017 Jul 5;12(1):126.
   PubMedGoogle Scholar
• Pozzi E, Giorgio E, Mancini C, et al. In vitro dexamethasone treatment does not induce alternative ATM transcripts in cells from ataxia-telangiectasia patients. Sci Rep. 2020 Nov 19;10(1):20182.
   PubMed Web of Science ®Google Scholar
• Zielen S, Whitehouse W, Magnani M, et al. The pivotal multi-center, randomized, double-blind, placebo-controlled trial of intra-erythrocyte dexamethasone sodium phosphate (ATTeST) on the neurological motor function of people with ataxia telangiectasia. American Academy of Neurology 2022 Annual Meeting; 2022 Apr 5; Seattle, Washington, USA; 2022.
   Google Scholar
• Cortina-Borja M, Te Vruchte D, Mengel E, et al. Annual severity increment score as a tool for stratifying patients with Niemann-Pick disease type C and for recruitment to clinical trials. Orphanet J Rare Dis. 2018 Aug 16;13(1):143.
   PubMedGoogle Scholar
• Brueggemann A, Bicvic A, Goeldlin M, et al. Effects of Acetyl-DL-Leucine on ataxia and downbeat-nystagmus in six patients with ataxia telangiectasia. J Child Neurol. 2022 Jan;37(1):20–27. doi: 10.1177/08830738211028394
   PubMed Web of Science ®Google Scholar
• Saberi-Karimian M, Beyraghi-Tousi M, Mirzadeh M, et al. The effect of N-Acetyl-DL-Leucine on neurological symptoms in a patient with ataxia-telangiectasia: a case study. Cerebellum. 2023 Feb;22(1):96–101. doi: 10.1007/s12311-022-01371-x
   PubMed Web of Science ®Google Scholar
• Fields T, Patterson M, Bremova-Ertl T, et al. A master protocol to investigate a novel therapy acetyl-L-leucine for three ultra-rare neurodegenerative diseases: Niemann-Pick type C, the GM2 gangliosidoses, and ataxia telangiectasia. Trials. 2021 Jan 22;22(1):84. doi: 10.1186/s13063-020-05009-3
   PubMed Web of Science ®Google Scholar
• Zhang L, Jia Y, Qi X, et al. Trihexyphenidyl for treatment of dystonia in ataxia telangiectasia: a case report. Childs Nerv Syst. 2020 Apr;36(4):873–875. doi: 10.1007/s00381-019-04399-3
   PubMed Web of Science ®Google Scholar
• Nissenkorn A, Hassin-Baer S, Lerman SF, et al. Movement disorder in ataxia-telangiectasia: treatment with amantadine sulfate. J Child Neurol. 2013 Feb;28(2):155–160. doi: 10.1177/0883073812441999
   PubMed Web of Science ®Google Scholar
• Thompson S, Iyer A, Byrd P, et al. Dopa-responsive dystonia and chorea as a presenting feature in ataxia-telangiectasia. Mov Disord Clin Pract. 2014 Sep;1(3):249–251. doi: 10.1002/mdc3.12048
   PubMedGoogle Scholar
• Charlesworth G, Mohire MD, Schneider SA, et al. Ataxia telangiectasia presenting as dopa-responsive cervical dystonia. Neurology. 2013 Sep 24;81(13):1148–1151.
   PubMed Web of Science ®Google Scholar
• Arıcan P, Dündar NO, Kırbıyık Ö, et al. Variant ataxia-telangiectasia in a child presenting with laryngeal dystonia. Turk J Pediatr. 2020;62(3):491–494. doi: 10.24953/turkjped.2020.03.019
   PubMed Web of Science ®Google Scholar
• Yorek MA, Dunlap JA, Manzo-Fontes A, et al. Abnormal myo-inositol and phospholipid metabolism in cultured fibroblasts from patients with ataxia telangiectasia. Biochim Biophys Acta. 1999 Mar 25;1437(3):287–300.
   PubMed Web of Science ®Google Scholar
• Lavin MF, Gueven N, Bottle S, et al. Current and potential therapeutic strategies for the treatment of ataxia-telangiectasia. Br Med Bull. 2007;81-82(1):129–147. doi: 10.1093/bmb/ldm012
   PubMedGoogle Scholar
• Shaikh AG, Marti S, Tarnutzer AA, et al. Effects of 4-aminopyridine on nystagmus and vestibulo-ocular reflex in ataxia-telangiectasia. J Neurol. 2013 Nov;260(11):2728–2735. doi: 10.1007/s00415-013-7046-4
   PubMed Web of Science ®Google Scholar
• Suarez F, Mahlaoui N, Canioni D, et al. Incidence, presentation, and prognosis of malignancies in ataxia-telangiectasia: a report from the French national registry of primary immune deficiencies. J Clin Oncol. 2015 Jan 10;33(2):202–208.
   PubMed Web of Science ®Google Scholar
• Bakhtiar S, Salzmann-Manrique E, Donath H, et al. The incidence and type of cancer in patients with ataxia-telangiectasia via a retrospective single-centre study. Br J Haematol. 2021 Sep;194(5):879–887. doi: 10.1111/bjh.17736
   PubMed Web of Science ®Google Scholar
• McKinnon PJ. ATM and the molecular pathogenesis of ataxia telangiectasia. Annu Rev Pathol Mech Dis. 2012;7(1):303–321. doi: 10.1146/annurev-pathol-011811-132509
   PubMedGoogle Scholar
• Weyl Ben Arush M, Rosenthal J, Dale J, et al. Ataxia telangiectasia and lymphoma: an indication for individualized chemotherapy dosing–report of treatment in a highly inbred Arab family. Pediatr Hematol Oncol. 1995 Mar;12(2):163–169. doi: 10.3109/08880019509029550
   PubMed Web of Science ®Google Scholar
• Chen RL, Wang PJ, Hsu YH, et al. Severe lung fibrosis after chemotherapy in a child with ataxia-telangiectasia. J Pediatr Hematol Oncol. 2002 [2002 Jan];24(1):77–79. doi: 10.1097/00043426-200201000-00021
   PubMed Web of Science ®Google Scholar
• Schoenaker MH, Suarez F, Szczepanski T, et al. Treatment of acute leukemia in children with ataxia telangiectasia (A-T). Eur J Med Genet. 2016 Dec;59(12):641–646. doi: 10.1016/j.ejmg.2016.05.012
   PubMed Web of Science ®Google Scholar
• Upadhyaya SA, Mody R, Walkovich K, et al. Ataxia telangiectasia and Cancer predisposition: challenges in management. J Pediatr Hematol Oncol. 2018 Aug;40(6):483–486. doi: 10.1097/MPH.0000000000001005
   PubMed Web of Science ®Google Scholar
• Rossi G, Zecca M, Marchi A, et al. Modified chop-chemotherapy plus rituximab for diffuse large b-cell lymphoma complicating ataxia-telangiectasia. Br J Haematol. 2003 Jan;120(2):369–371. doi: 10.1046/j.1365-2141.2003.04041_4.x
   PubMed Web of Science ®Google Scholar
• Shabbat S, Aharoni J, Sarid L, et al. Rituximab as monotherapy and in addition to reduced CHOP in children with primary immunodeficiency and non-Hodgkin lymphoma. Pediatr Blood Cancer. 2009 May;52(5):664–666. doi: 10.1002/pbc.21808
   PubMed Web of Science ®Google Scholar
• Machida S, Tomizawa D, Tamaichi H, et al. Successful treatment of diffuse large B-cell lymphoma in a patient with ataxia telangiectasia using rituximab. J Pediatr Hematol Oncol. 2013 Aug;35(6):482–485. doi: 10.1097/MPH.0b013e3182804d59
   PubMed Web of Science ®Google Scholar
• Czarny J, Andrzejewska M, Zając-Spychała O, et al. Successful treatment of large B-Cell lymphoma in a child with compound heterozygous mutation in the ATM gene. Int J Mol Sci. 2023 Jan 6;24(2):1099.
   PubMed Web of Science ®Google Scholar
• Kropshofer G, Wehl G, Klein-Franke A, et al. B-cell lymphoma in a girl with ataxia teleangiectasia (A-T) treated with rituximab monotherapy. Pediatr Blood Cancer. 2006 Apr;46(4):528–529. doi: 10.1002/pbc.20548
   PubMed Web of Science ®Google Scholar
• Meister MT, Voss S, Schwabe D. Treatment of EBV-associated nodular sclerosing Hodgkin lymphoma in a patient with ataxia telangiectasia with brentuximab vedotin and reduced COPP plus rituximab.Pediatr Blood Cancer. 2015 [2015 Nov];62(11):2018–2020. doi: 10.1002/pbc.25621
   PubMed Web of Science ®Google Scholar
• Alakaya M, Gundogan BD, Arslankoylu AE, et al. Pediatric EBV positive mucocutaneous ulceration in stomach a rare entity. J Pediatr Hematol Oncol. 2022 Mar 1;44(2):e503–e506.
   PubMed Web of Science ®Google Scholar
• Pietzner J, Baer PC, Duecker RP, et al. Bone marrow transplantation improves the outcome of atm-deficient mice through the migration of ATM-competent cells. Hum Mol Genet. 2013 Feb 1;22(3):493–507.
   PubMed Web of Science ®Google Scholar
• Duecker R, Baer PC, Buecker A, et al. Hematopoietic stem cell transplantation restores naïve T-Cell populations in atm-deficient mice and in preemptively treated patients with ataxia-telangiectasia. Front Immunol. 2019;10:2785. doi: 10.3389/fimmu.2019.02785
   PubMed Web of Science ®Google Scholar
• Duecker RP, Gronau L, Baer PC, et al. Survival and functional immune reconstitution after haploidentical stem cell transplantation in atm-deficient mice. Front Immunol. 2021;12:693897. doi: 10.3389/fimmu.2021.693897
   PubMed Web of Science ®Google Scholar
• Mehta PA, Davies SM, Leemhuis T, et al. Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study. Blood. 2017 Apr 20;129(16):2308–2315.
   PubMed Web of Science ®Google Scholar
• Bakhtiar S, Woelke S, Huenecke S, et al. Pre-emptive allogeneic hematopoietic stem cell transplantation in ataxia telangiectasia. Front Immunol. 2018;9:2495. doi: 10.3389/fimmu.2018.02495
   PubMed Web of Science ®Google Scholar
• Ghosh S, Schuster FR, Binder V, et al. Fatal outcome despite full lympho-hematopoietic reconstitution after allogeneic stem cell transplantation in atypical ataxia telangiectasia. J Clin Immunol. 2012 Jun;32(3):438–440. doi: 10.1007/s10875-012-9654-7
   PubMed Web of Science ®Google Scholar
• Ussowicz M, Musiał J, Duszeńko E, et al. Long-term survival after allogeneic-matched sibling PBSC transplantation with conditioning consisting of low-dose busilvex and fludarabine in a 3-year-old boy with ataxia-telangiectasia syndrome and ALL. Bone Marrow Transplant. 2013 May;48(5):740–741. doi: 10.1038/bmt.2012.207
   PubMed Web of Science ®Google Scholar
• Beier R, Sykora KW, Woessmann W, et al. Allogeneic-matched sibling stem cell transplantation in a 13-year-old boy with ataxia telangiectasia and EBV-positive non-Hodgkin lymphoma. Bone Marrow Transplant. 2016 Sep;51(9):1271–1274. doi: 10.1038/bmt.2016.93
   PubMed Web of Science ®Google Scholar
• Ussowicz M, Wawrzyniak-Dzierżek E, Mielcarek-Siedziuk M, et al. Allogeneic stem cell transplantation after Fanconi Anemia conditioning in children with ataxia-telangiectasia results in stable T cell engraftment and lack of infections despite mixed chimerism. Biol Blood Marrow Transplant. 2018 Nov;24(11):2245–2249. doi: 10.1016/j.bbmt.2018.07.001
   PubMed Web of Science ®Google Scholar
• Usatin D, Yen EH, McDonald C, et al. Differences between WHO and CDC early growth measurements in the assessment of cystic fibrosis clinical outcomes. J Cyst Fibros. 2017 Jul;16(4):503–509. doi: 10.1016/j.jcf.2016.12.001
   PubMed Web of Science ®Google Scholar
• Schroeder SA, Swift M, Sandoval C, et al. Interstitial lung disease in patients with ataxia-telangiectasia. Pediatr Pulmonol. 2005 [2005 Jun];39(6):537–543. doi: 10.1002/ppul.20209
   PubMed Web of Science ®Google Scholar
• Taylor AM, Rosney CM, Campbell JB. Unusual sensitivity of ataxia telangiectasia cells to bleomycin. Cancer Res. 1979 Mar;39(3):1046–1050.
   PubMed Web of Science ®Google Scholar
• Sandoval C, Swift M. Commentary: appropriate cancer chemotherapy for ataxia-telangiectasia patients. Med Pediatr Oncol. 2000 Jan;34(1):65–66. doi: 10.1002/(SICI)1096-911X(200001)34:1<65:AID-MPO15>3.0.CO;2-8
   PubMedGoogle Scholar
• Connelly PJ, Smith N, Chadwick R, et al. Recessive mutations in the cancer gene ataxia telangiectasia mutated (ATM), at a locus previously associated with metformin response, cause dysglycaemia and insulin resistance. Diabet Med. 2016 Mar;33(3):371–375. doi: 10.1111/dme.13037
   PubMed Web of Science ®Google Scholar
• Viniegra JG, Martínez N, Modirassari P, et al. Full activation of PKB/Akt in response to insulin or ionizing radiation is mediated through ATM. J Biol Chem. 2005 Feb 11;280(6):4029–4036.
   PubMed Web of Science ®Google Scholar
• Yang DQ, Kastan MB. Participation of ATM in insulin signalling through phosphorylation of eIF-4E-binding protein 1. Nat Cell Biol. 2000 Dec;2(12):893–898. doi: 10.1038/35046542
   PubMed Web of Science ®Google Scholar
• Donath H, Hess U, Kieslich M, et al. Diabetes in patients with ataxia telangiectasia: a national cohort study. Front Pediatr. 2020;8:317. doi: 10.3389/fped.2020.00317
   PubMed Web of Science ®Google Scholar
• Zhou K, Bellenguez C, Spencer CC, et al. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nature Genet. 2011 Feb;43(2):117–120.
   PubMed Web of Science ®Google Scholar
• Voss S, Pietzner J, Hoche F, et al. Growth retardation and growth hormone deficiency in patients with ataxia telangiectasia. Growth Factors. 2014 Jun;32(3–4):123–129. doi: 10.3109/08977194.2014.939805
   PubMed Web of Science ®Google Scholar
• Woelke S, Pommerening H, Kieslich M, et al. Growth hormone treatment in patients with ataxia telangiectasia. Growth Factors. 2017 Jun;35(2–3):125–130. doi: 10.1080/08977194.2017.1367681
   PubMed Web of Science ®Google Scholar
• Buchbinder D, Hauck F, Albert MH, et al. Rubella virus-associated Cutaneous granulomatous disease: a unique complication in immune-deficient patients, not limited to DNA repair disorders. J Clin Immunol. 2019 Jan;39(1):81–89. doi: 10.1007/s10875-018-0581-0
   PubMed Web of Science ®Google Scholar
• Mitra A, Pollock B, Gooi J, et al. Cutaneous granulomas associated with primary immunodeficiency disorders. Br J Dermatol. 2005 Jul;153(1):194–199. doi: 10.1111/j.1365-2133.2005.06619.x
   PubMed Web of Science ®Google Scholar
• Woelke S, Valesky E, Bakhtiar S, et al. Treatment of granulomas in patients with ataxia telangiectasia. Front Immunol. 2018;9:2000. doi: 10.3389/fimmu.2018.02000
   PubMed Web of Science ®Google Scholar
• Corbisier A, Eschard C, Motte J, et al. Cutaneous granulomatous lesions disclosing ataxia-telangiectasia. Ann Dermatol Venereol. 1999 Aug;126(8–9):608–611.
   PubMed Web of Science ®Google Scholar
• Paller AS, Massey RB, Curtis MA, et al. Cutaneous granulomatous lesions in patients with ataxia-telangiectasia. J Pediatr. 1991 [1991 Dec];119(6):917–922. doi: 10.1016/S0022-3476(05)83043-4
   PubMed Web of Science ®Google Scholar
• Privette ED, Ram G, Treat JR, et al. Healing of granulomatous skin changes in ataxia-telangiectasia after treatment with intravenous immunoglobulin and topical mometasone 0.1% ointment. Pediatr Dermatol. 2014 [2014 Nov];31(6):703–707. doi: 10.1111/pde.12411
   PubMed Web of Science ®Google Scholar
• Browne R, Cliffe L, Ip W, et al. A case of wild-type rubella-associated cutaneous granuloma in ataxia telangiectasia. Pediatr Dermatol. 2022 Jul;39(4):619–621. doi: 10.1111/pde.15032
   PubMed Web of Science ®Google Scholar
• Faisthalab R, Suppiah S, Dorsey M, et al. Drug sensitivity of vaccine-derived rubella viruses and quasispecies evolution in granulomatous lesions of two ataxia-telangiectasia patients treated with nitazoxanide. Pathogens. 2022 Mar 11;11(3):338.
   PubMed Web of Science ®Google Scholar
• Mitra A, Gooi J, Darling J, et al. Infliximab in the treatment of a child with cutaneous granulomas associated with ataxia telangiectasia. J Am Acad Dermatol. 2011 Sep;65(3):676–677. doi: 10.1016/j.jaad.2010.06.060
   PubMed Web of Science ®Google Scholar
• Meyer AK, Banks M, Nadasdy T, et al. Vasculitis in a child with the hyper-IgM variant of ataxia-telangiectasia. Front Pediatr. 2019;7:390. doi: 10.3389/fped.2019.00390
   PubMed Web of Science ®Google Scholar
• Baumann U, Schulte JH, Groß JP, et al. Case report: Rubella virus-induced cutaneous granulomas in two pediatric patients with DNA double strand breakage repair disorders - outcome after hematopoietic stem cell transplantation. Front Immunol. 2022;13:886540. doi: 10.3389/fimmu.2022.886540
   PubMedGoogle Scholar
• Hui CW, Song X, Ma F, et al. Ibuprofen prevents progression of ataxia telangiectasia symptoms in ATM-deficient mice. J Neuroinflammation. 2018 Nov 6;15(1):308.
   PubMedGoogle Scholar